7.780USD+2.91%Mkt Cap: 1.45B USDP/E: —Last update: 2026-05-22
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidat…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap1.45B USD
Enterprise Value1.30B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.86M USD
Revenue/Share—
Last Price7.780 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS81642T2096
Valuation
P/E (Trailing)—
P/E (Forward)-50.40
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B16.33
EPS (TTM)-0.23
EPS (Forward)-0.15
52W Range
1.39083% of range9.100
52W High9.100 USD
52W Low1.390 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-37.90%
ROA-34.29%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.39M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.22%
Net Debt-106.23M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio17.22
Quick Ratio16.59
Book Value/Sh0.4630 USD
Cash/Share0.5760 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 8, 2019
Splits
Last Split1:50
Split DateNov 8, 2019
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)10.00 USD
Target Range10.00 USD – 10.00 USD
# Analysts2
Ownership
Shares Out.186.03M
Float185.23M
Insiders0.43%
Institutions29.22%
Short Interest
Short Ratio11.6d
Short % Float31.10%
Short % Out.30.97%
Shares Short57.15M
Short (prev mo.)53.53M
Technical
SMA 505.238 (+48.5%)
SMA 2003.288 (+136.6%)
Beta2.24
S&P 52W Chg28.31%
Avg Vol (30d)7.48M
Avg Vol (10d)13.18M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—